ANA Therapeutics, a Silicon Valley-based biotech startup, and Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, today announced a partnership to support the manufacturing of ANA Therapeutics’ drug candidate, ANA001 (niclosamide capsules), which they are developing as a potential treatment for COVID-19. As part of the collaboration, Quotient will scale up the capsule formulation, characterize and optimize the manufacturing process and ensure continuity of drug product through clinical trials.

Laboratory experiments have shown niclosamide stops SARS-CoV-2 (the virus that causes
COVID-19) from replicating, making it a promising candidate for reducing the spread of COVID-19. Niclosamide was previously approved by the FDA as a treatment for tapeworm and although not currently marketed in the U.S., it is on the World Health Organization’s List of Essential Medicines and has been used for decades to safely treat millions of people around the world.

“We have selected Quotient Sciences as our development and manufacturing partner and our plan is simple,” said Andrew Bartynski, COO, ANA Therapeutics. “Niclosamide has the potential to be an effective antiviral agent to combat COVID-19, and our top goal is to complete a clinical trial to determine its efficacy in treating patients with COVID-19. Quotient’s speed and agility will play a key role in reaching that important milestone.”

Mark Egerton, Ph.D., CEO of Quotient Sciences, said, “We are proud to partner with ANA Therapeutics in their pursuit of a treatment to fight this coronavirus pandemic. Our experience and flexible manufacturing approaches will enable ANA Therapeutics to initiate clinical testing in an accelerated timeframe.”

Under the scope of the agreement, ANA Therapeutics will access Quotient’s formulation and manufacturing expertise to develop and rapidly supply drug product for pivotal clinical trials in Q3 2020. The program will be conducted at Quotient’s facility in Garnet Valley, Pennsylvania.

This article was written by Medilink EM Patron, Quotient Sciences.

For more information on Medilink East Midlands Patronage, click here

Latest Opportunities

Grant and funding opportunities report from Health Innovation East

Health Innovation East has developed a grant opportunities report to help you know what may…

University of Nottingham calling decision-makers to participate in survey

The University of Nottingham invites you to participate in their survey, designed to understand your…

Expression of Interest: Cohort 2 Health Innovation East Digital Hub

Who is this programme suitable for: Small and medium-sized enterprises, along with clinical entrepreneurs and…

Latest News

Record level of government R&D investment seen in Autumn Budget 2024

Chancellor Rachel Reeves announced a record level of government R&D investment in the Autumn Budget…

eg technology launches Technology Readiness Level assessment

eg technology’s Technology Readiness Level (TRL) assessment is a practical way for innovators to assess…

Guardtech Group win fourth award in two months with Cleancube shipping container facility innovation

The Guardtech Group has claimed a fourth awards success in the space of just two…